Skip To Main Content
Dajin Zou on Muck Rack

Dajin Zou

As seen in: Color Research & Application
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Dajin

Contact Dajin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Comparative Effectiveness and Safety of Different Basal Insulins in a Real World Setting

|
By Linong Ji, Puhong Zhang, Dongshan Zhu, Juming Lu, Xiaohui Guo, Yangfeng Wu, Xian Li, Jiachao Ji, Weiping Jia, Wenying Yang, Dajin Zou, Zhiguang Zhou, Yan Gao, Satish K. Garg, Changyu Pan, Jianping Weng, Sanjoy K. Paul
| Color Research & Application Verified
To compare glucose control and safety of different basal insulin (BI, including Insulin NPH, glargine and detemir) therapies in real-life clinical settings based on a large-scale registry study. In this multi-center 6-month prospective observational study, patients with type 2 diabetes uncontrolled (HbA1c?7%) by oral anti-diabetic drugs (OADs) and willing to initiate BI were enrolled from 209 hospitals of eight regions of China.
Open in Who Shared Issue with article?

Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in China - Ji - 2017 - Diabetes, Obesity and Metabolism - Wiley Online Library

|
By Linong Ji, Xian Li, Jiachao Ji, Weiping Jia, Jianping Weng, Zhiguang Zhou, Changyu Pan, Yan Gao, Puhong Zhang, Dongshan Zhu, Juming Lu, Xiaohui Guo, Yangfeng Wu, Wenying Yang, Dajin Zou, Satish K. Garg
| Color Research & Application Verified
Overall, 18,995 patients inadequately controlled [HbA 1c ? 53 mmol/mol (7%)] with oral antihyperglycaemic drugs (OADs) and willing to receive BI treatment were registered at 209 hospitals and followed at baseline (visit 1), 3 months (visit 2), and 6 months (visit 3). Type of BI was initiated at physicians’ discretion. Retention with BI therapy at 6 months was 75.6%.
Open in Who Shared Issue with article?
See all 2 articles